DPYSL2 and cancer: The binding of DPYSL2 to PKM2 can inhibit the formation of tetrameric PKM2, resulting in an increase in the level of dimeric PKM2, switching glucose metabolism in cancer cells from the normal respiratory pathway to aerobic glycolysis to promote cancer cell proliferation and growth, which is the same as the results in our prognostic model.